An internal standard for the quantification of tranexamic acid
Tranexamic acid 13C2,15N is intended for use as an internal standard for the quantification of tranexamic acid by GC- or LC-MS. Tranexamic acid is an inhibitor of fibrinolysis that inhibits the interaction of plasmin with fibrin (IC50 = 3.1 μM in isolated human plasma).1 It reduces increases in the expression of the profibrogenic genes Timp1 and Col1a1, but not Itgb6, Tgfβ1, or Tgfβ2, and increases in hepatic protein levels of cytokeratin 19 (CK19) and type I collagen induced by α-naphthylisothiocyanate (AINT) after 28 days in a mouse model of chronic bile duct injury.2
|1. Bostr?m, J., Grant, J.A., Fjellstr?m, O., et al. Potent fibrinolysis inhibitor discovered by shape and electrostatic complementarity to the drug tranexamic acid. J. Med. Chem. 56(8), 3273-3280 (2013).|2. Joshi, N., Kopec, A.K., Towery, K., et al. The antifibrinolytic drug tranexamic acid reduces liver injury and fibrosis in a mouse model of chronic bile duct injury. J. Pharmacol. Exp. Ther. 349(3), 383-392 (2014).
动态评分
0.0